openheart.bmj8h
Global, regional and national burdens of cardiovascular disease attributable to secondhand smoke from 1990–2019: an age-period-cohort analysis
Background Over the past three decades, significant disparities in the global burden of cardiovascular disease (CVD) have ...
openheart.bmj8h
Association of blood pressure and left ventricular mass with subclinical coronary atherosclerosis
Background Left ventricular (LV) mass is closely associated with atherosclerotic heart disease, but the mechanisms are not ...
openheart.bmj8h
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...
openheart.bmj5d
Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF
Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...
openheart.bmj19h
Revealing the limitations of 10-year MACE observations: 20-year observed total cardiovascular burden in the EPIC-Norfolk study
Background Primary prevention strategies for cardiovascular disease (CVD) conventionally rely on 10-year risk estimates of major adverse cardiovascular events (MACE). However, communicating ...